Arbutus Biopharma Corp (ABUS) Receives Average Recommendation of “Hold” from Brokerages

Arbutus Biopharma Corp (NASDAQ:ABUS) has been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $13.80.

ABUS has been the subject of several analyst reports. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. ValuEngine downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. BidaskClub downgraded Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. Finally, Leerink Swann reissued a “market perform” rating and set a $5.00 target price (up from $4.00) on shares of Arbutus Biopharma in a research note on Tuesday, November 7th.

Arbutus Biopharma (NASDAQ:ABUS) traded down $0.10 on Wednesday, reaching $5.65. The company’s stock had a trading volume of 101,900 shares, compared to its average volume of 190,015. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. The stock has a market cap of $311.04, a P/E ratio of -1.13 and a beta of 1.12. Arbutus Biopharma has a 12-month low of $2.55 and a 12-month high of $8.25.

Several hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its stake in shares of Arbutus Biopharma by 309.1% during the 4th quarter. Millennium Management LLC now owns 82,007 shares of the biopharmaceutical company’s stock worth $414,000 after buying an additional 61,961 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Arbutus Biopharma during the 4th quarter worth approximately $215,000. Goldman Sachs Group Inc. purchased a new position in shares of Arbutus Biopharma during the 4th quarter worth approximately $275,000. Deutsche Bank AG raised its stake in shares of Arbutus Biopharma by 24.8% during the 4th quarter. Deutsche Bank AG now owns 163,451 shares of the biopharmaceutical company’s stock worth $825,000 after buying an additional 32,451 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Arbutus Biopharma by 150.7% during the 4th quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock worth $2,033,000 after buying an additional 241,963 shares in the last quarter. 63.44% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma Corp (ABUS) Receives Average Recommendation of “Hold” from Brokerages” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/19/arbutus-biopharma-corp-abus-receives-average-recommendation-of-hold-from-brokerages.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply